HONG KONG & BOSTON & DURHAM, N.C.--(BUSINESS WIRE)--Parexel, a leading provider of solutions to accelerate the development and delivery of innovative new therapies to market to improve world health, from Clinical through to Commercialization, today announced the expansion of its capabilities to optimize drug development and commercialization in Asia/Pacific through a new Hong Kong presence established by its strategic healthcare consulting Health Advances subsidiary.
The opening of Health Advances Asia Limited leverages the firm’s 20-plus years of experience in the Asia/Pacific region to help both local and multi-national companies looking to expand their global footprint. Health Advances’ locally-based, multilingual Hong Kong team will be led by Gary Cheng, who joins Health Advances with more than 30 years’ experience in the pharma, biotech, and medtech industries with such companies as Novartis, BD, Chiron Corporation, Alere, and Aventis (acquired by Sanofi). Additionally, Vivek Mittal, a long-time Partner at Health Advances in its San Francisco office, is now also based in Hong Kong and will work closely with Gary and the rest of the team to assist clients with their business needs.
Health Advances provides business strategy, scientific and clinical expertise along with a deep knowledge of product development considerations, referral patterns and economic conditions that can impact the adoption of healthcare products and services. Health Advances’ strategic consulting is a key component of Parexel Biotech, the company’s division focused on helping emerging companies chart the fastest, most-efficient course to accomplish their drug development goals. Health Advances’ local team, along with its more than 160 global employees, will provide strategic consulting support to the healthcare industry across Asia/Pacific, including Greater China, Japan, South Korea, Australia, India and South East Asian Countries.
“For both local companies in Asia/Pacific and global companies looking to expand into the region, taking advantage of the rapid economic growth in the local healthcare market requires thoughtful and strategic business decisions,” said Paula Ness Speers, Health Advances’ Co-Founder and Managing Director. “Building on our long history of helping companies explore and evaluate opportunities in the Asia/Pacific region and assisting locally-based companies looking to expand beyond their borders, we’re excited to have part of our consulting team now based full-time on the ground in the region to readily support customers in this growing market.” She continued, “Under Vivek and Gary’s leadership, our local team is well-equipped to help clients across the healthcare sector, including biopharmaceutical, medtech, diagnostics, health IT and digital health, and healthcare services as well as investors in healthcare businesses understand and capitalize on both local and global opportunities.”
With Health Advances Asia Limited, Parexel now has eight offices, more than 1,700 employees across all functions in Greater China and more than 8,000 employees in the Asia/Pacific region.
About Parexel
Parexel is focused on supporting the development of innovative new therapies to improve patient health. We do this through a suite of services that help life science and biopharmaceutical customers across the globe transform scientific discoveries into new treatments for patients. From clinical trials to regulatory and consulting services to commercial and market access, our therapeutic, technical and functional ability is underpinned by a deep conviction in what we do. For more information, visit our website and follow us on LinkedIn, Twitter and Instagram.
Parexel is a registered trademark of Parexel International Corporation. All other trademarks are the property of their respective owners.
